Skip to content
CNS Clinical Research

Birmingham, Alabama

CNS clinical trials in Birmingham, AL

54 CNS studies are recruiting participants at sites in Birmingham as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.

Call (888) 520-7418
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Birmingham at a glance

  • 54 studies are recruiting at a site in Birmingham.
  • By phase: Early Phase 1 (1), Phase 1 (2), Phase 1/2 (2), Phase 2 (5), Phase 2/3 (2), Phase 3 (13), Phase 4 (3), No phase (17), Observational (9). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (26), university, hospital or other (26), government (2).
  • By research area: Depression (14), Parkinson's Disease (12), Epilepsy (11), Multiple Sclerosis (10), Migraine (3), Schizophrenia (3), ADHD (1).
  • Most recent update to one of these records: November 16, 2026.

Depression studies recruiting in Birmingham

Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    University of Alabama
    Registry record
    NCT07226661 · updated
  2. Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

    • No phase
    • Ages 12 to 22
    • All sexes
    Sponsor
    Michigan State University
    Study site
    University of Alabama Birmingham Hospital
    Registry record
    NCT06232304 · updated
  3. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    UAB Psychiatry and Behavioral Neurology
    Registry record
    NCT06793397 · updated
  4. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    UAB, Psychiatry and Behavioral Neurology
    Registry record
    NCT07002034 · updated
  5. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    LivaNova
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT03887715 · updated
  6. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07227454 · updated
  7. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    University of Alabama at Birmingham - School of Medicine
    Registry record
    NCT07775300 · updated
  8. Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    VA Office of Research and Development
    Study site
    Birmingham VA Medical Center, Birmingham, AL
    Registry record
    NCT07226232 · updated
  9. Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

    • No phase
    • Ages 22 to 70
    • All sexes
    Sponsor
    Abbott Medical Devices
    Study site
    University of Alabama at Birmingham - Dept. of Psychiatry
    Registry record
    NCT06423430 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Birmingham, AL on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Birmingham

  1. Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

    • Phase 1
    • Ages 18 to 80
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Study site
    Wellness, Health and Research Facility at UAB
    Registry record
    NCT07557706 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Alabama- Birmingham ( Site 5015)
    Registry record
    NCT07216703 · updated
  3. A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

    • Phase 3
    • Ages 50 to 85
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07174310 · updated
  4. A Study of Buntanetap in Participants With PD

    • Phase 2/3
    • Ages 40 to 85
    • All sexes
    Sponsor
    Annovis Bio Inc.
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07284784 · updated
  5. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated
  6. Stimulus-Evoked Directional Field Potentials to Guide Subthalamic and Pallidal DBS for PD

    • No phase
    • Ages 18 to 89
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT06169852 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Birmingham, AL on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Birmingham

  1. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT06433752 · updated
  2. A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    Alabama Neurology Associates
    Registry record
    NCT07609719 · updated
  3. A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Celgene
    Study site
    Alabama Neurology Associates
    Registry record
    NCT06782490 · updated
  4. Care in Multiple Sclerosis (MS)

    • Observational
    • Ages 18 to 29
    • All sexes
    Sponsor
    NYU Langone Health
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07011914 · updated
  5. Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    TG Therapeutics, Inc.
    Study site
    TG Therapeutics Investigational Trial Site
    Registry record
    NCT05877963 · updated
  6. A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Alabama Neurology Associates PC
    Registry record
    NCT07225504 · updated
  7. Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis

    • No phase
    • Ages 18 to 64
    • All sexes
    Sponsor
    University of Alabama at Birmingham
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT07475377 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Birmingham, AL on ClinicalTrials.gov.

Epilepsy studies recruiting in Birmingham

  1. Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Rapport Therapeutics Inc.
    Registry record
    NCT07563881 · updated
  2. Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Neurona Therapeutics
    Study site
    University of Alabama
    Registry record
    NCT05135091 · updated
  3. A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    • Phase 3
    • Ages 2 and older
    • All sexes
    Sponsor
    Epygenix
    Study site
    University of Alabama at Birmingham
    Registry record
    NCT04462770 · updated
  4. Diagnosing Epilepsy To EffeCT Change

    • No phase
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    UAB Epilepsy Center
    Registry record
    NCT07110337 · updated
  5. Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

    • Observational
    • Ages 18 to 75
    • All sexes
    Sponsor
    Epiminder America, Inc.
    Study site
    UAB Epilepsy Center
    Registry record
    NCT07110454 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Birmingham, AL on ClinicalTrials.gov.

Migraine studies recruiting in Birmingham

  1. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Central Research Associates, LLC (CRA) dba Flourish Research
    Registry record
    NCT07645924 · updated
  2. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Central Research Associates, LLC (CRA) dba Flourish Research
    Registry record
    NCT07674654 · updated
  3. Responding With Evidence and Access for Childhood Headaches

    • No phase
    • Ages 10 to 17
    • All sexes
    Sponsor
    Children's Hospital Medical Center, Cincinnati
    Study site
    University of Alabama at Birmingham Children's of Alabama
    Registry record
    NCT05889624 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Birmingham, AL on ClinicalTrials.gov.

Ask about studies near Birmingham

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 520-7418

or send a short form

How should we reach you?

Call